giredestrant
Selected indexed studies
- Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. (J Clin Oncol, 2024) [PMID:38537155]
- GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer. (J Med Chem, 2021) [PMID:34251202]
- Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. (Lancet Oncol, 2023) [PMID:37657462]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer. (2024) pubmed
- Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. (2024) pubmed
- GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer. (2021) pubmed
- Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. (2023) pubmed
- Giredestrant Delivers Long-Sought Adjuvant Benefit. (2026) pubmed
- Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer. (2024) pubmed
- Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer. (2022) pubmed
- heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. (2024) pubmed
- Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer. (2024) pubmed
- Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review. (2024) pubmed